KROS
Keros Therapeutics, Inc.
There isn't enough reported data to score KROS yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
KROS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
KROS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
KROS PE Valuation
KROS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
KROS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect KROS's losses to grow, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
KROS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.34 | -251% |
| Q2 2026 | -$3.22 | -1106% |
| Q1 2026 | -$2.53 | -$2.36 |
| Q4 2025 | $2.30 | +$7.30 |
| Q3 2025 | $1.55 | +$6.76 |
| Q2 2025 | $0.32 | +$5.45 |
| Q1 2025 | -$0.17 | +$4.98 |
| Q4 2024 | -$5.00 | +$0.20 |
KROS has swung to a loss: it lost $2.34 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over KROS on earnings quality, reporting a profit while its opponent remains loss making.
KROS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40M | +183% |
| Q1 2026 | $367K | -100% |
| Q4 2025 | $380K | -88% |
| Q3 2025 | $14.1M | +3540% |
| Q2 2025 | $18.2M | +49003% |
| Q1 2025 | $211.2M | +254348% |
| Q4 2024 | $3M | +2027% |
| Q3 2024 | $388K | +4750% |
KROS's revenue is recovering but still below its 2025 peak: $40M last quarter, up 183% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | +141 points |
| Q1 2026 | -7051% | -7123 points |
| Q4 2025 | -7703% | -5952 points |
| Q3 2025 | -109% | +15009 points |
| Q2 2025 | -219% | +136103 points |
| Q1 2025 | 72% | +58485 points |
| Q4 2024 | -1751% | +30735 points |
| Q3 2024 | -15118% | +525882 points |
KROS's operating margin was 32% last quarter, up 251 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over KROS on profitability, with a higher operating margin.
KROS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.3M | +6.9% |
| Q2 2026 | -$20.6M | +$9.8M |
| Q1 2026 | -$3.6M | -102% |
| Q4 2025 | -$27.4M | +$18.9M |
| Q3 2025 | $3.1M | +$34M |
| Q2 2025 | -$30.3M | +$9.8M |
| Q1 2025 | $160.6M | +$206.1M |
| Q4 2024 | -$46.3M | -$20.3M |
KROS has burned cash in almost every quarter: −$48M over the past year, against $87M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over KROS on cash generation, producing positive trailing cash flow while its opponent burns cash.
KROS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +541K shares |
| 1 year | -50% | -20.3M shares |
| 3 years | -31% | -9.3M shares |
| 5 years | -13% | -3M shares |
| Available history | +129% | +11.5M shares |
KROS has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
KROS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -4.2x | Net Cash |
| Q3 2025 | -15.4x | Net Cash |
| Q2 2025 | -412.8x | Net Cash |
KROS has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
KROS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 29.8 | Neutral |
KROS's weekly RSI is 43 (neutral) and its Stochastic is 30 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
KROS PE vs Healthcare Sector
| Metric | KROS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KROS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
KROS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 7.7% below |
| 20 week MA | $10.9 | 7.5% below |
| 50 week MA | $13.0 | 22% below |
| 100 week MA | $13.5 | 25% below |
| 200 week MA | $30.6 | 67% below |
KROS is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over KROS on trend strength, trading above more of its moving averages.
KROS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.6 | $78.5 | +264% |
| 2021 | $78.5 | $58.8 | -25% |
| 2022 | $58.8 | $46.7 | -21% |
| 2023 | $46.7 | $39.8 | -15% |
| 2024 | $39.8 | $16.4 | -59% |
| 2025 | $16.4 | $21.0 | +28% |
| 2026 YTD | $21.0 | $10.1 | -52% |
KROS's yearly returns have swung widely, from +264% in 2020 to −59% in 2024. It's down 52% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over KROS on returns for 2026, with the stronger performance.